Wednesday, May 15, 2024

Laekna Therapeutics and Innovent Biologics Obtain IND Approval for Combination Therapy For Tumor patients

Laekna Therapeutics announced that the investigational new drug (IND) application of a combination therapy for the phase 1/2 clinical trial in patients with solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Laekna Therapeutics is an emerging innovative biopharmaceutical company focused on developing groundbreaking and innovative therapies to treat cancer and liver diseases. The IND approval marks a key milestone under the clinical research partnership Laekna and Innovent formed in July 2021.

Also Read: Optimvia and Ginkgo Bioworks Announce Partnership to Manufacture Biosynthetic Heparin

The imminent phase 1/2 dose escalation study will evaluate the efficacy and safety of the combination of afuresertib (LAE002), sintilimab and chemotherapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors. The Principal Investigator of the study is Professor Shen Lin, Vice President of Peking University Hospital and Cancer Institute and Director of the Department of Gastrointestinal Oncology. The combination therapy includes Laekna Therapeutics‘ pan-AKT kinase inhibitor afresertib, Innovent’s sintilimab, and albumin-bound paclitaxel or docetaxel.

The phase 1 study aims to evaluate the safety of the three-drug combination, and determine the recommended phase 2 dose (RP2D). The phase 2 study will aim to evaluate the clinical efficacy and safety of the combination therapy in patients who have been refractory to treatment with PD-1/PD-L1 inhibitors (monotherapy or in combination with other oncology drugs) and who have suffered from one of the following five types of tumors:

  • Non-small cell lung cancer (NSCLC)
  • Gastric cancer/gastro-oesophageal junction cancer (GC/GEJC)
  • Esophageal cancer (EsC)
  • Cervical cancer (CC)
  • Endometrial cancer (EC)

Professor Shen Lin explains, “As a serine/threonine kinase, AKT is a potential new target for cancer treatment. The results of multiple preclinical studies has showed that inhibiting AKT has the potential to restore the sensitivity of cancer cells to oncology therapies. Therapy resistance remains a common clinical problem and challenge for the further application of PD-1/PD-L1 blockade therapies despite their promising prospects. Statistics has showed that only some patients are estimated to have a positive response to PD-1/PD-L1 blockade therapies. In additional, for most patients with initial clinical response, acquired resistance remains a significant challenge. I have high expectations for this clinical trial involving an AKT inhibitor, and I hope it will provide a new treatment option for patients with specific solid tumors refractory to treatment with PD-1/PD-L1 inhibitors.”

Laekna Therapeutics Chairman and CEO Dr. Chris Lu commented, “A document recently released by the CDE, ‘Guiding Principles for Clinical Research of Antitumor Pharmaceuticals Based on Clinical Value’, specifically mentions that ‘tumor resistance is a major challenge that cancer treatments and new medicines face during development’.

Subscribe Now

    Hot Topics